Inhibition of the VEGF receptor 2 (VEGFR2), which is a dominant receptor in the angiogenesis of tumor tissue, by the systemic injection of the RGD-MEND into tumor-bearing mice resulted in tumor regression via an anti-angiogenic effect. This evidence concerns the gene KDR and neoplasm.